Linked Life Data

17318917

Source:http://linkedlifedata.com/resource/pubmed/id/17318917

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-3-13
pubmed:abstractText
The ability to detect and characterize atherosclerosis with targeted contrast agents may enable initiation of therapy for atherosclerotic lesions prior to becoming symptomatic. Since lipoproteins such as high-density lipoprotein (HDL) and low-density lipoprotein (LDL) play a critical role in the regulation of plaque biology through the transport of lipids into and out of atherosclerotic lesions, modifying HDL and LDL with radioisotopes for nuclear imaging, chelates for magnetic resonance imaging (MRI) or other possible contrast agents for computed tomography imaging techniques may aid in the detection and characterization of atherosclerosis. This review focuses on the literature employing lipoproteins as contrast agents for imaging atherosclerosis and the feasibility of this approach.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1555-4317
pubmed:author
pubmed:copyrightInfo
Copyright 2007 John Wiley & Sons, Ltd.
pubmed:issnType
Electronic
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
16-23
pubmed:dateRevised
2010-10-29
pubmed:meshHeading
pubmed:articleTitle
Modified lipoproteins as contrast agents for imaging of atherosclerosis.
pubmed:affiliation
Instituto de Ciencia Molecular (ICMOL), Universidad de Valencia, Valencia, Spain. juan.frias@uv.es
pubmed:publicationType
Journal Article, Review